•  
  •  
  •  
  •  

2026-02-12 22:30:13

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Tamilnad Mercantile Bank Credits Oracle Fusion Cloud Applications for AI-Powered Efficiency Gains
  • Nifty Rises for The Third Straight Session, Closes at One-Month High
  • Skybags Partners with Chennai Super Kings as Official Luggage Partner for 2026
  • Persistent Recognized as the Fastest Growing IT Services Brand Globally in the 2026 Brand Finance IT Services 25 Report
  • Axis Bank launches Gold Loan for MSMEs with high loan-to-value and same-day disbursement

Keywords Selected:  Biotechnology

Research

  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

Stock Report

  • Fitch Ratings Revises Biocon Biologics Outlook from 'Stable' to 'Positive'
  • Phase III Clinical Trial of DengiAll® by ICMR and Panacea Biotec - Completion of enrollment of study participants
  • Vivo Bio Tech Ltd receives GLP compliance from NGCMA
  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM
  • Biocon Limited launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Biocon Ltd to integrate Biocon Biologics Ltd to create a Unified Global Biopharmaceutical Leader
  • Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World
  • Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Panacea Biotec Ltd receives acceptance from CMSS for supply of bOPV
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Panacea Biotec Ltd receives LoA from UNICEF
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • Panacea Biotec Launches India's first 100% toxin-free and safe NikoMom Baby Skin Care
  • Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • Vivo Bio Tech Ltd secures landmark Pre-Clinical Testing Contract Valued at ₹10.75 Crores

Latest Post

  • Tamilnad Mercantile Bank Credits Oracle Fusion Cloud Applications for AI-Powered Efficiency Gains
  • Nifty Rises for The Third Straight Session, Closes at One-Month High
  • Skybags Partners with Chennai Super Kings as Official Luggage Partner for 2026
  • Persistent Recognized as the Fastest Growing IT Services Brand Globally in the 2026 Brand Finance IT Services 25 Report
  • Axis Bank launches Gold Loan for MSMEs with high loan-to-value and same-day disbursement


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025